Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

Plain-language summary

This study examines liquid biopsy from blood together with the machine-learning-based BEACON approach to detect early-stage colorectal cancer, adenomas, Lynch syndrome-related cancers, and residual disease after treatment. Individuals who had a colonoscopy at the time of blood sampling and went through standard diagnostic procedures can take part. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

San Raffaele University

Intervention

BEACON

Start date

1/1/2024

Estimated completion

8/15/2031

Countries

Italy

Related genes

Locations

• Milan, Italy
• Milan, Italy
• Milan, Italy
• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.
* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment

Exclusion Criteria:

* Lack of informed consent
* Inflammatory bowel disease